Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience

•Patients with extremes of body weight (EBW) are underrepresented in clinical trials.•Effect of EBW on the drug level with standard dose of rivaroxaban was assessed.•Rivaroxaban levels were significantly higher in patients of weight < 50 kg than others.•Bleeding & recurrent VTE rates were not associated with drug levels or body weight.